BRPI0507451A - method and combination therapy to inhibit tumor growth and / or metastatic progression and / or development of metastases, and use of an anti-alpha4 integrin immunoglobulin - Google Patents

method and combination therapy to inhibit tumor growth and / or metastatic progression and / or development of metastases, and use of an anti-alpha4 integrin immunoglobulin

Info

Publication number
BRPI0507451A
BRPI0507451A BRPI0507451-7A BRPI0507451A BRPI0507451A BR PI0507451 A BRPI0507451 A BR PI0507451A BR PI0507451 A BRPI0507451 A BR PI0507451A BR PI0507451 A BRPI0507451 A BR PI0507451A
Authority
BR
Brazil
Prior art keywords
metastases
tumor growth
development
inhibit tumor
combination therapy
Prior art date
Application number
BRPI0507451-7A
Other languages
Portuguese (pt)
Inventor
Nancy Wehner
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of BRPI0507451A publication Critical patent/BRPI0507451A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MéTODO E TERAPIA COMBINADA PARA INIBIR O CRESCIMENTO DE TUMOR E/OU PROGRESSãO METASTáTICA E/OU DESENVOLVIMENTO DE METáSTASES, E, USO DE UMA IMUNOGLOBULINA ANTI- ALFA4 INTEGRINA Composições, métodos e terapias combinadas para o tratamento de linfomas, leucemias, melanomas, câncer de próstata, e doença metastática são providos. Especificamente, as composições compreendendo imunoglobulinas anti-<244>4 integrina ou imunoglobulinas que se ligam a um ligando de <244>4 integrina (por exemplo MadCAM-1 e VCAM-1) são descritos para uso na inibição do crescimento de tumor e progressão e inibição de metástases. Uma imunoglobulina preferida para uso no tratamento de tumores e metástases é natalizumab. As composições e métodos usando estas imunoglobulinas podem ser usados sozinhos ou em combinação com outros reagentes e modalidades de tratamento de câncer.METHOD AND COMBINED THERAPY TO INHIBIT TUMOR GROWTH AND / OR METHASTATIC PROGRESS AND / OR METHODASE DEVELOPMENT, AND USE OF ANTI-ALPHA4 INTEGRINE IMMUNOGLOBULIN Combined compositions, methods and therapies for the treatment of lymphomas, leukemias, leukemias, cancer, prostate, and metastatic disease are provided. Specifically, compositions comprising anti-β4 integrin immunoglobulins or immunoglobulins that bind to a β4 integrin ligand (e.g. MadCAM-1 and VCAM-1) are described for use in inhibiting tumor growth and progression. and inhibition of metastases. A preferred immunoglobulin for use in the treatment of tumors and metastases is natalizumab. Compositions and methods using these immunoglobulins may be used alone or in combination with other cancer treatment reagents and modalities.

BRPI0507451-7A 2004-02-06 2005-02-03 method and combination therapy to inhibit tumor growth and / or metastatic progression and / or development of metastases, and use of an anti-alpha4 integrin immunoglobulin BRPI0507451A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54194604P 2004-02-06 2004-02-06
PCT/US2005/002860 WO2005076843A2 (en) 2004-02-06 2005-02-03 Methods and compositions for treating tumors and metastatic disease

Publications (1)

Publication Number Publication Date
BRPI0507451A true BRPI0507451A (en) 2007-07-10

Family

ID=34860234

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507451-7A BRPI0507451A (en) 2004-02-06 2005-02-03 method and combination therapy to inhibit tumor growth and / or metastatic progression and / or development of metastases, and use of an anti-alpha4 integrin immunoglobulin

Country Status (19)

Country Link
US (1) US20050255118A1 (en)
EP (2) EP2394652A3 (en)
JP (1) JP4996261B2 (en)
KR (1) KR20070009581A (en)
CN (1) CN1946407B (en)
AR (1) AR047534A1 (en)
AU (1) AU2005213324B2 (en)
BR (1) BRPI0507451A (en)
CA (1) CA2555365A1 (en)
EA (1) EA009873B1 (en)
IL (1) IL177201A0 (en)
MX (1) MXPA06008746A (en)
NO (1) NO20063951L (en)
NZ (1) NZ584288A (en)
PE (1) PE20060009A1 (en)
TW (1) TWI375563B (en)
UY (1) UY28741A1 (en)
WO (1) WO2005076843A2 (en)
ZA (1) ZA200606557B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
ES2362667T3 (en) 2004-01-09 2011-07-11 Pfizer Inc. ANTIBODIES AGAINST MAdCAM.
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
EP2109460B1 (en) 2007-01-11 2016-05-18 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
JP2011506322A (en) * 2007-12-07 2011-03-03 エラン ファーマシューティカルズ，インコーポレイテッド Methods and compositions for treating humoral tumors
GB0800311D0 (en) * 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
US20110110940A1 (en) * 2008-04-15 2011-05-12 Oxigene, Inc. Methods for Enhancing the Efficacy of Vascular Disrupting Agents
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
AU2010236257A1 (en) * 2009-04-17 2011-11-03 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
US20110158982A1 (en) * 2009-10-05 2011-06-30 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
ES2654820T3 (en) 2010-10-25 2018-02-15 Biogen Ma Inc. Methods to determine differences in alpha-4-integrin activity by correlating differences in sVCAM and / or sMAdCAM levels
WO2013013302A1 (en) * 2011-07-22 2013-01-31 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
EP3795145A3 (en) * 2011-08-17 2021-06-09 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
WO2014018913A2 (en) * 2012-07-27 2014-01-30 University Of Connecticut Santacruzamate a compositions and analogs and methods of use
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
RU2527154C1 (en) * 2013-03-27 2014-08-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method for increasing cisplatin bioavailability in experimentally induced sarcoma 45
ES2728305T3 (en) * 2013-04-29 2019-10-23 Ogd2 Pharma Use as an O-acetylated GD2 ganglioside target as a new therapeutic and diagnostic strategy for cancer stem cell cancer
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
AU2015209133B2 (en) 2014-01-24 2019-10-03 AI Therapeutics, Inc. Apilimod compositions and methods for using same
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
CN106715676A (en) 2014-09-26 2017-05-24 泰尔茂比司特公司 Scheduled feed
BR112017008799A2 (en) 2014-11-07 2017-12-19 Lam Therapeutics Inc apilimod compositions and methods of use in treating kidney cancer
RU2731908C2 (en) 2014-11-07 2020-09-09 ЭйАй ТЕРАПЬЮТИКС, ИНК. Apilimod composition and methods of using it in treating melanoma
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
RU2650587C1 (en) * 2017-04-26 2018-04-16 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method of the melanoma b16 malignant growth in mice modification with chronic pain
EP3652211A1 (en) 2017-07-14 2020-05-20 Pfizer Inc. Antibodies to madcam
JP2022500419A (en) * 2018-09-13 2022-01-04 ンカルタ・インコーポレイテッドNkarta, Inc. Natural killer cell compositions and immunotherapeutic methods for treating tumors
MX2021010670A (en) 2019-03-05 2021-11-12 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy.
RU2762730C1 (en) * 2021-03-30 2021-12-22 Елена Рудольфовна Милаева Means for inhibiting metastasis in the lungs
RU2765955C1 (en) * 2021-03-30 2022-02-07 Елена Рудольфовна Милаева Pulmonary metastasis inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
DK0678122T3 (en) * 1993-01-12 2000-03-06 Biogen Inc Recombinant anti-VLA4 antibody molecules
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6027726A (en) 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
AU733692B2 (en) * 1997-02-28 2001-05-24 Regents Of The University Of California, The Inhibition of cell-cell binding by lipid assemblies
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
SI1113810T1 (en) * 1998-09-14 2009-04-30 Univ Texas Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding
DK1242118T3 (en) 1999-12-16 2010-01-11 Biogen Idec Inc Methods for treating ischemic or hemorrhagic damage to the central nervous system using anti-alpha4 integrin antagonists
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
US6894033B2 (en) * 2001-06-11 2005-05-17 Transition Therapeutics Inc. Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
EP1423135A4 (en) * 2001-08-06 2006-06-07 Univ California Methods for inhibiting angiogenesis
AR038605A1 (en) * 2002-02-25 2005-01-19 Elan Pharm Inc USE OF AGENTS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF INFLAMMATION AND COMPOSITIONS FOR SUCH TREATMENT
EP1682179A4 (en) * 2003-11-05 2008-09-03 Palingen Inc Enhanced b cell cytotoxicity of cdim binding antibody
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor

Also Published As

Publication number Publication date
EP2394652A2 (en) 2011-12-14
EP1718310A2 (en) 2006-11-08
PE20060009A1 (en) 2006-02-11
EP2394652A3 (en) 2012-10-24
CA2555365A1 (en) 2005-08-25
AR047534A1 (en) 2006-01-25
TWI375563B (en) 2012-11-01
NZ584288A (en) 2011-10-28
IL177201A0 (en) 2006-12-10
MXPA06008746A (en) 2007-01-23
AU2005213324A1 (en) 2005-08-25
KR20070009581A (en) 2007-01-18
US20050255118A1 (en) 2005-11-17
JP4996261B2 (en) 2012-08-08
TW200536556A (en) 2005-11-16
AU2005213324B2 (en) 2011-06-09
CN1946407A (en) 2007-04-11
UY28741A1 (en) 2005-08-31
WO2005076843A2 (en) 2005-08-25
EA009873B1 (en) 2008-04-28
JP2007520557A (en) 2007-07-26
NO20063951L (en) 2006-11-02
CN1946407B (en) 2011-10-05
ZA200606557B (en) 2008-02-27
WO2005076843A3 (en) 2006-01-26
EP1718310A4 (en) 2009-05-06
EA200601433A1 (en) 2007-02-27

Similar Documents

Publication Publication Date Title
BRPI0507451A (en) method and combination therapy to inhibit tumor growth and / or metastatic progression and / or development of metastases, and use of an anti-alpha4 integrin immunoglobulin
Schottelius et al. [111 In] PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
BR0210550A (en) Method to enhance the effectiveness of cancer therapies
BRPI0612845A8 (en) compound, pharmaceutical formulation, methods for treating cancer and for synthesizing a compound of formula
UA116188C2 (en) PHOSPHATIDYLINOSITE-3-KINASE INHIBITORS AND METHODS OF USE
BRPI0515850A (en) transport agents derived from cupredoxin and methods of using them
CL2007001624A1 (en) Use of an antibody that binds to dll4 for the treatment of tumor, cancer or cell proliferation disorder.
CL2008000785A1 (en) Compounds derived from 4 - ((7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido [4,5-b] [1,4] diazepin-2- yl) amino) -3-methoxybenzamide; intermediate compound; pharmaceutical composition, useful to treat cancer.
BRPI0510177B8 (en) compound, pharmaceutical composition and use thereof
NL300418I1 (en) Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascitis
BR9805544C1 (en) Use of a compound.
BRPI1014637A2 (en) mesothelin immunoconjugates and their use
BR112022020769A2 (en) CD73-INHIBITING COMPOUNDS OF 2,4-DIOXOPYRIMIDINE
ATE531388T1 (en) USE OF ANTI-ALPHA5BETA1 ANTIBODIES TO INHIBIT CANCER CELL PROLIFERATION
BRPI0407680A (en) methods for cancer diagnosis and cancer cell metastasis reduction
MA34878B1 (en) USE OF SIGMA LIGANDS FOR BONE CANCER PAIN
Cleveland et al. Cutaneous fibrosis induced by docetaxel: a case report
Lee Osteosarcoma in Korean children and adolescents
DE60328772D1 (en) EPOTHILONE DERIVATIVE FOR THE TREATMENT OF HEPATOMA AND OTHER CANCER DISORDERS
Sakashita et al. The incidence of late neck recurrence in N0 maxillary sinus squamous cell carcinomas after superselective intra-arterial chemoradiotherapy without prophylactic neck irradiation
NO20055650L (en) Ruteinum (II) complexes for the treatment of tumors
UA88294C2 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
Zhao et al. Combination of ibrutinib with ABT-199, a BCL-2 pathway inhibitor: effective therapeutic strategy in a novel mantle cell lymphoma cell line model
DE50311665D1 (en) GUANIDINOPHENYLALANINE COMPOUNDS AS UROKINASE INHIBITORS
Liu et al. Induction of cyclin D1 by arsenite and UVB-irradiation in human keratinocytes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.